Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis

Ke Ren, Hongjiang Yuan, Yijia Zhang, Xin Wei, Dong Wang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A macromolecular prodrug (P-Dex) of dexamethasone (Dex) was developed to improve the treatment of inflammatory bowel disease (IBD). Colonic inflammation was induced by feeding mice with dextran sulfate sodium. Mice were treated with daily i.p. injection of free Dex or single i.v. injection of P-Dex, PBS or free polymer. Both P-Dex and free Dex could lower disease activity index and histology scores when compared to the controls. A single injection of P-Dex with 1/4 equivalent Dex dose had a better therapeutic effect than daily free Dex treatment. Mechanism study found that P-Dex could target the inflamed colon, and be retained by epithelial cells and local inflammatory infiltrates, suggesting that the improved efficacy of P-Dex may be attributed to its inflammation targeting, subcellular processing and activation. Collectively, these data support our hypothesis that the development of macromolecular prodrug of glucocorticoid may have the potential to improve the clinical management of IBD.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalClinical Immunology
Volume160
Issue number1
DOIs
StatePublished - Sep 1 2015

Fingerprint

Dextran Sulfate
Prodrugs
Ulcerative Colitis
Dexamethasone
Glucocorticoids
Therapeutics
Inflammatory Bowel Diseases
Injections
Inflammation
Therapeutic Uses
Histology
Polymers
Colon
Epithelial Cells

Keywords

  • Dextran sulfate sodium
  • ELVIS
  • Glucocorticoid
  • HPMA copolymer
  • Inflammatory bowel diseases
  • Prodrug

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis. / Ren, Ke; Yuan, Hongjiang; Zhang, Yijia; Wei, Xin; Wang, Dong.

In: Clinical Immunology, Vol. 160, No. 1, 01.09.2015, p. 71-81.

Research output: Contribution to journalArticle

@article{289f221060e04b0b810c94ef823ecc45,
title = "Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis",
abstract = "A macromolecular prodrug (P-Dex) of dexamethasone (Dex) was developed to improve the treatment of inflammatory bowel disease (IBD). Colonic inflammation was induced by feeding mice with dextran sulfate sodium. Mice were treated with daily i.p. injection of free Dex or single i.v. injection of P-Dex, PBS or free polymer. Both P-Dex and free Dex could lower disease activity index and histology scores when compared to the controls. A single injection of P-Dex with 1/4 equivalent Dex dose had a better therapeutic effect than daily free Dex treatment. Mechanism study found that P-Dex could target the inflamed colon, and be retained by epithelial cells and local inflammatory infiltrates, suggesting that the improved efficacy of P-Dex may be attributed to its inflammation targeting, subcellular processing and activation. Collectively, these data support our hypothesis that the development of macromolecular prodrug of glucocorticoid may have the potential to improve the clinical management of IBD.",
keywords = "Dextran sulfate sodium, ELVIS, Glucocorticoid, HPMA copolymer, Inflammatory bowel diseases, Prodrug",
author = "Ke Ren and Hongjiang Yuan and Yijia Zhang and Xin Wei and Dong Wang",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.clim.2015.03.027",
language = "English (US)",
volume = "160",
pages = "71--81",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis

AU - Ren, Ke

AU - Yuan, Hongjiang

AU - Zhang, Yijia

AU - Wei, Xin

AU - Wang, Dong

PY - 2015/9/1

Y1 - 2015/9/1

N2 - A macromolecular prodrug (P-Dex) of dexamethasone (Dex) was developed to improve the treatment of inflammatory bowel disease (IBD). Colonic inflammation was induced by feeding mice with dextran sulfate sodium. Mice were treated with daily i.p. injection of free Dex or single i.v. injection of P-Dex, PBS or free polymer. Both P-Dex and free Dex could lower disease activity index and histology scores when compared to the controls. A single injection of P-Dex with 1/4 equivalent Dex dose had a better therapeutic effect than daily free Dex treatment. Mechanism study found that P-Dex could target the inflamed colon, and be retained by epithelial cells and local inflammatory infiltrates, suggesting that the improved efficacy of P-Dex may be attributed to its inflammation targeting, subcellular processing and activation. Collectively, these data support our hypothesis that the development of macromolecular prodrug of glucocorticoid may have the potential to improve the clinical management of IBD.

AB - A macromolecular prodrug (P-Dex) of dexamethasone (Dex) was developed to improve the treatment of inflammatory bowel disease (IBD). Colonic inflammation was induced by feeding mice with dextran sulfate sodium. Mice were treated with daily i.p. injection of free Dex or single i.v. injection of P-Dex, PBS or free polymer. Both P-Dex and free Dex could lower disease activity index and histology scores when compared to the controls. A single injection of P-Dex with 1/4 equivalent Dex dose had a better therapeutic effect than daily free Dex treatment. Mechanism study found that P-Dex could target the inflamed colon, and be retained by epithelial cells and local inflammatory infiltrates, suggesting that the improved efficacy of P-Dex may be attributed to its inflammation targeting, subcellular processing and activation. Collectively, these data support our hypothesis that the development of macromolecular prodrug of glucocorticoid may have the potential to improve the clinical management of IBD.

KW - Dextran sulfate sodium

KW - ELVIS

KW - Glucocorticoid

KW - HPMA copolymer

KW - Inflammatory bowel diseases

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=84940447445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940447445&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2015.03.027

DO - 10.1016/j.clim.2015.03.027

M3 - Article

C2 - 25869296

AN - SCOPUS:84940447445

VL - 160

SP - 71

EP - 81

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -